5 Energizing Snack Recipes to Make Ahead and Eat All Week
The word 'snack' often conjures up images of indulgent treats and empty calories eaten for pure pleasure. But not only can mindful snacking be part of a healthy diet, but eating a nutritious mini-meal can help you sustain your energy levels throughout the day. Especially if you have a long lag between breakfast and lunch, or lunch and dinner. If you have a little time to meal prep, these make-ahead snack recipes are for you.
Related:
Whether you're hiking a forest trail or navigating the urban jungle (or jungle gym), keep a stash of this 3-ingredient trail mix on hand to maintain balanced energy levels throughout the day. The recipe calls for a trio of tropical ingredients: dried mango, coconut flakes, and cashews. Feel free to substitute any nuts you have on hand.
Try the recipe from .
Cucumber sandwiches are a staple of high tea. Perhaps it's because they're rich in Vitamin B5, which is known to help boost energy levels. We suggest you make this classic late-afternoon snack with whole wheat bread and a bit of Greek yogurt to double down on the energizing effects.
Try the recipe from .
This healthy take on Almond Joy candy bars is just the thing when you're craving something chocolatey. It just takes 15 minutes to whip up 40 sticky-sweet energy balls that will keep for a couple of weeks.
Try the recipe from .
If you've got a bag of edamame in your freezer and staples like olive oil, salt, and pepper in your pantry, you've got everything you need to bake up a batch of this addictive, high-protein snack that's so much better than store-bought.
Try the recipe from .
You don't have to follow the keto diet to love these low-carb turkey roll-ups. Just dab a tablespoon of tangy French onion spread on a slice of deli turkey, top it with a crunchy mix of cucumbers, bell peppers, and greens (or whatever other veggies you've got in the fridge), and roll for a super fresh and energizing snack.
Try the recipe from .
The post 5 Energizing Snack Recipes to Make Ahead and Eat All Week appeared first on Clean Plates.
Related Headlines
Why I'll never fly without Travelzoo — savings, perks, and peace of mind
5 Drinks High in Magnesium, Say Dietitians
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 hours ago
- Yahoo
How your MP voted in assisted dying bill
Assisted dying is one step closer to becoming legal in the UK following a landmark vote in the House of Commons. A Bill that would allow terminally ill adults with a life expectancy of less than six months to end their lives was backed by a majority of MPs today (Friday). It came despite warnings from opponents, who argued it had been rushed through Parliament. During a three hour debate on Friday, MPs on both sides of the issue recalled personal stories of loved ones who had died. READ MORE: UK Ryanair Boeing 737 flight crashes at Greek airport READ MORE: Why UK heatwaves feel hotter than 30C heat abroad Former Conservative minister Sir James Cleverly, who led the opposition to the Bill in the Commons, spoke of a close friend who died 'painfully' from cancer. He said he comes at the divisive issue 'not from a position of faith nor from a position of ignorance', and was driven in his opposition by 'concerns about the practicalities' of the Bill. See how your MP voted in the widget below... Encouraging or assisting suicide is currently against the law in England and Wales, with a maximum jail sentence of 14 years. But the proposed legislation took another step in the parliamentary process, which means the Bill will move to the House of Lords for further debate and scrutiny. Labour MP Kim Leadbeater has argued her Bill will 'correct the profound injustices of the status quo and to offer a compassionate and safe choice to terminally ill people who want to make it'. Due to the four-year implementation period, it could be 2029 – potentially coinciding with the end of this Government's Parliament – before assisted dying is offered. Today's historic vote was the first time the Bill was debated and voted on in its entirety since last year, when MPs supported the principle of assisted dying for England and Wales by a majority of 55 at second reading. MPs voted 314 to 291, majority 23, to approve Ms Leadbeater's Terminally Ill Adults (End of Life) Bill at third reading. They had a free vote on the Bill, meaning they decided according to their conscience rather than along party lines.
Business Wire
2 days ago
- Business Wire
Brenus Pharma and InSphero Have Developed 3D Tumor Spheroids Mimicking
LISBON, Portugal--(BUSINESS WIRE)--Brenus Pharma, a French biotech developing next-generation first-in-class immunotherapies, and InSphero, a Swiss leader in 3D cell-based assay technologies, presented promising data at the European Association for Cancer Research 2025 annual congress. These data confirm the use of 3D tumor spheroids for potency testing of STC-1010, Brenus' lead candidate for colorectal cancer. 'This collaboration has enabled us to assess the highly representative and scalable 3D model into our SGC platform. It's a major step forward in our ability to assess potency and accelerate the development of STC-1010 and future candidates.' Benoit Pinteur Share Funded through the EUROSTARS program, the collaboration led to vitrified 3D colorectal cancer spheroids using tumor cell lines co-cultured with fibroblasts. The vitrification method preserves morphology, stromal integrity, and viability after thawing, enabling realistic evaluation of STC-1010's therapeutic potential under conditions mimicking in vivo human tumors. Previous studies showed that STC-1010 antigens were effectively processed by monocyte-derived dendritic cells (mMo-DCs), activating CD8+ T cells. These T cells induced apoptosis in both 2D and 3D colorectal cancer models and released anti-tumor cytokines (IFNγ and Granzyme B). These data reinforce the therapeutic potential of STC-1010. ' This collaboration has enabled us to assess the highly representative and scalable 3D model into our SGC platform. It's a major step forward in our ability to assess potency and accelerate the development of STC-1010 and future candidates.' Benoit Pinteur, CSO of Brenus Pharma. ' We are proud to support Brenus with our cryopreserved 3D tumor models. This work illustrates how advanced in vitro systems can bring immunotherapies closer to clinical reality.' Jan Lichtenberg, CEO of InSphero. About Brenus Pharma Brenus Pharma unlocks the potential of immuno-oncology by generating first-in-class immunotherapies that initiate a multi-specific in vivo immune response against tumors. Their proprietary 'off-the-shelf' Stimulated-tumor-Ghost-Cells (SGC) platform mimics patients' tumor cells and makes them visible to the immune system to anticipate, target, and destroy these cells as they appear. Brenus aims to shift the oncology paradigm by making patients active participants in their treatment.
Yahoo
3 days ago
- Yahoo
Pierre Fabre Laboratories Begins Next Chapter in Secaucus, NJ
SECAUCUS, N.J., June 18, 2025 /PRNewswire/ -- Pierre Fabre Laboratories, a global healthcare company originated from France, announces the inauguration of its new US office located on 500 Plaza Drive, in Secaucus, NJ which will host its dermo-cosmetics and medical care subsidiaries. Pierre Fabre is the world's second-largest dermo-cosmetics manufacturer and a global player in oncology, cell & gene therapy, rare disease and dermatology. This strategic move in the US marks a pivotal moment in the company's growth strategy, underscoring its strong commitment to advancing in the US in both dermo-cosmetics and medical care. Pierre Fabre Laboratories introduced global dermo-cosmetics brands Avène, Klorane and René Furterer to the US market in the 1990's. With an ever-growing desire for French dermo-cosmetics, the US dermo-cosmetics business has become a top priority. Building upon their success in oncology and dermatology in Europe and Asia, the company has recently expanded its medical care investments in the US through the creation of a dedicated pharmaceutics unit, Pierre Fabre Pharmaceuticals (PFP). This subsidiary is focused on continuing to deliver breakthrough therapies in rare diseases and oncology to American patient populations with high unmet needs and limited treatment options. Eric Ducournau, CEO of Pierre Fabre Laboratories states, "we have declared the United States a priority geography for the company. The US is not only the biggest market in the world for pharmaceuticals and cosmetics alike, but also the most disruptive market for therapeutic innovation. For 15 years, we have built strategic partnerships with highly innovative US biotechnology companies in the fields of oncology, rare diseases, and medical dermatology. We have also multiplied by 10 times the turnover of our blockbuster brand Eau Thermale Avène since 2010, and its potential remains huge given the growing appetite of American consumers for cosmetics designed and tested with the same rigor as for medicines. We are now determined to walk the next step forward and the opening of our new office in Secaucus with plans to expand in the rare diseases and oncology business is a testimony to this dedication." Secaucus, NJ offers a strategic location with excellent transportation links to New York City and the broader tri-state area. Designed to represent the company's core values, the office showcases its deep respect for the environment, a commitment to sustainable innovation and allows for hands on learning through an onsite space that offers an immersive skin and hair care experience. This thoughtfully curated environment is engineered to spark creativity and foster teamwork across all departments. "This new office is more than just a space, it's a hub for collaboration, innovation, and showcases the team's hard work and dedication. It embodies the Group's commitment to pushing boundaries across both business units in derm-cosmetics and pharmaceutics, while providing New Ways to Care for all" said Lisa Morris, President and CEO of Pierre Fabre USA. "Today's office opening demonstrates the steadfast commitment of Pierre Fabre Laboratories to building a powerful presence for medical innovation and patient impact in the US," said Adriana Herrera, CEO of PFP. "Leveraging our strength as a humanitarian foundation owned company, PFP has been focused over the past 18-months on building the US Medical Care operations and to bring on board an experienced, agile and purpose driven US team focused on creating long-term value and hope for patients, by delivering innovative therapies to people living with cancer who are in urgent need of effective, life-extending treatment options." With this new footprint in the US, Pierre Fabre Laboratories is positioning itself for even greater impact with American patients and healthcare professionals in dermo-cosmetics and pharmaceuticals. For the company, this is only the beginning. For more information, visit or follow @aveneusa on Instagram Note: High-resolution images, interviews, and product samples are available upon request. ABOUT PIERRE FABRE LABORATORIES Pierre Fabre Laboratories is the world's second-largest dermo-cosmetics company and one of Europe's leading pharmaceutical laboratories. Its Dermo-cosmetics & Personal Care portfolio includes international brands such as Eau Thermale Avène, Ducray, Klorane, A-Derma, René Furterer, Même Cosmetics, Darrow, and Elgydium. Its Medical Care activity covers 5 main therapeutic fields: oncology, dermatology, rare diseases, primary care, and family health care. In 2024, Pierre Fabre Laboratories posted 3.1 billion euros in revenues, 70% of which came from international sales in 120 countries. Based in southwest France since its creation and manufacturing nearly 90% of its products in France, Pierre Fabre Laboratories employs 10,200 people worldwide. Its R&D budget amounted to 220 million euros in 2024, of which 60% is allocated to targeted therapies in oncology and 35% to skin health and care solutions. Pierre Fabre Laboratories' majority shareholder (86%) is an eponymous humanitarian Foundation. Employees constitute the company's other shareholders. This capital structure guarantees the company's independence, long-term vision, and contribution to the common good. The dividends paid to the Pierre Fabre Foundation contribute to 35 healthcare-access programs deployed in 22 of the least developed countries in the world. Pierre Fabre Laboratories' CSR policy has been assessed by AFNOR Certification and has been awarded the "Exemplary" level of its CSR label (ISO 26 000 standard for sustainable development). For more information, visit Media Contact:Elena Suarez-Peñ View original content to download multimedia: SOURCE Avène USA
